Search Result

Results for "

carboxypeptidase N

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Carboxypeptidase (2) Aminopeptidase (1) Apoptosis (2) Autophagy (2) Bcl-2 Family (2) Biochemical Assay Reagents (2) Bradykinin Receptor (1) Fluorescent Dye (1) GLP Receptor (2) Insulin Receptor (2) Interleukin Related (1) Isotope-Labeled Compounds (3) mGluR (1) p38 MAPK (2) α-synuclein (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Metabolic Disease (3) Neurological Disease (3)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Carboxypeptidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W704574

Mergetpa	Carboxypeptidase Bradykinin Receptor Interleukin Related	Cardiovascular Disease Metabolic Disease
Mergetpa is a reversible *Arg-carboxypeptidase* inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P4522

Bz-Ala-Arg	Biochemical Assay Reagents	Others
Bz-Ala-Arg is a dipeptide. Bz-Ala-Arg is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .

HY-P4522A

Bz-Ala-Arg TFA	Biochemical Assay Reagents	Others
Bz-Ala-Arg TFA is a dipeptide. Bz-Ala-Arg TFA is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .

HY-103344

ZJ43	Aminopeptidase Carboxypeptidase mGluR	Neurological Disease
ZJ43 is a NAAG peptidase inhibitor and *glutamate carboxypeptidase* II/III (GCP II/III) inhibitor with human GCP II IC₅₀ of 2.4 nM and K_i of 0.8 nM. ZJ43 blocks N-acetylaspartylglutamate hydrolysis, elevates extracellular N-acetylaspartylglutamate levels, and activates group II metabotropic glutamate receptors (mGluR**). ZJ43 can be used for the research of schizophrenia, inflammatory pain, neuropathic pain, and traumatic brain injury .

HY-P3791

N-Succinyl-Ile-Ile-Trp-AMC	Fluorescent Dye	Others
N-Succinyl-Ile-Ile-Trp-AMC is a peptide-based fluorescent substrate or probe for carboxypeptidase Y (CPY) .

HY-176313S

Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cardiovascular Disease
Carboxypeptidase B2, Arg- ¹³C₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C-labeled and ¹⁵N-labeled Carboxypeptidase B2.

N-Succinyl-Ile-Ile-Trp-AMC	Fluorescent Dyes
N-Succinyl-Ile-Ile-Trp-AMC is a peptide-based fluorescent substrate or probe for carboxypeptidase Y (CPY) .

Cat. No.	Product Name	Target	Research Area

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P4522

Bz-Ala-Arg	Biochemical Assay Reagents	Others
Bz-Ala-Arg is a dipeptide. Bz-Ala-Arg is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .

HY-P4522A

Bz-Ala-Arg TFA	Biochemical Assay Reagents	Others
Bz-Ala-Arg TFA is a dipeptide. Bz-Ala-Arg TFA is also a substrate of human pancreatic carboxypeptidase B and plasma carboxypeptidase N .

HY-P3791

N-Succinyl-Ile-Ile-Trp-AMC	Fluorescent Dye	Others
N-Succinyl-Ile-Ile-Trp-AMC is a peptide-based fluorescent substrate or probe for carboxypeptidase Y (CPY) .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71559

	NAALADL2 Protein, Human (His-SUMO) Glutamate carboxypeptidase II type non peptidase homologue; Inactive N acetylated alpha linked acidic dipeptidase like protein 2; Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2; N acetylated alpha linked acidic dipeptidase like 2; NAALADase L2; NAALADL 2; NAALADL2	Human	E. coli
	The NAALADL2 protein was identified as catalytically inactive, suggesting a role beyond enzymatic activity. The name implies that non-enzymatic functions contribute to different cellular processes. NAALADL2 Protein, Human (His-SUMO) is the recombinant human-derived NAALADL2 protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-114118S1

Semaglutide-d8 tetraTFA
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-176313S

Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2
Carboxypeptidase B2, Arg- ¹³C₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C-labeled and ¹⁵N-labeled Carboxypeptidase B2.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.